general news

Day Zero announces $6.2M award in non-dilutive funding from CARB-X

Day Zero announces $6.2M award in non-dilutive funding from CARB-X
Day Zero announces $6.2M award in non-dilutive funding from CARB-X

Day Zero Diagnostics has recently announced over $6.2 million award from CARB-X in non-dilutive funding.

CARB-X is a non-profit partnership that is dedicated to speeding up the antibacterial research & development to tackle the increasing threats of drug-resistant bacteria, globally. The company focuses on the diagnostics of infectious diseases using ML and genome sequencing to fight antibiotic-resistant infections.

The funding will support the development of the company’s diagnostic system, intended to quickly assist physicians and accurately treat and diagnose bacterial infections. The main objective of the system is to immediately offer effective antibiotic treatment to patients, rather than being treated for multiple days with toxic broad-spectrum antibiotics to avert septic shock. The diagnostic system also aims at improving the outcomes of patients as well as transforming how hospitals monitor the transmission events, prepare for potential outcomes, and track the antibiotic resistance evolution.

In addition to the recent award of $6.2 million from CARB-X, Day Zero will be able to receive an additional award of $18.7 million as well as an access to expertise & business consulting resources, if the project meets the development milestone.

According to Jong Lee, Day Zero Diagnostics’ CEO, the ongoing COVID-19 pandemic has significantly demonstrated the importance of accurate and rapid diagnostics to combat the threats of infectious diseases. Antibiotic-resistant infections have long been a global threat, as they spread easily and can be extremely lethal. The company expressed appreciation towards the support from CARB-X to develop a new class of sequencing-based, culture-free diagnostics that can effectively fight these infections.

Funding from CARB-X will enable the company to completely develop the core technologies that will power Blood2Bac™ and other diagnostic systems. Blood2Bac™ is a proprietary technology that allows the ultra-high bacterial DNA enrichment from the clinical blood & Keynome®, the company’s ML algorithm for resistance profiling and species identification. It will also accelerate the expansion of MicrohmDB®, which is a proprietary large-scale database that combines the genomic sequences with the known susceptibility profiles and antibiotic resistance.

Source credit:

About the author

Bhushan Tambe

A qualified computer graduate, Bhushan Tambe always nurtured a passion for words. Post his education, he decided to transform his penchant of penning down poetry and stories into a full-time career. Presently, Bhushan writes numerous articles for and a few other websites, on subjects spanning business, finance, and the like.